| Baker Bros. Advisors Lp |
Non-Executive Director |
Kymera Therapeutics, Inc. (KYMR)
|
2024-08-20 |
$46.41 |
0.4% |
1
|
$46 |
| Baker Bros. Advisors Lp |
Non-Executive Director |
IGM Biosciences, Inc. (IGMS)
|
2024-03-28 |
$8.67 |
18.3% |
395,317
|
$3,425,569 |
| Baker Bros. Advisors Lp |
Non-Executive Director |
IGM Biosciences, Inc. (IGMS)
|
2023-12-15 |
$6.44 |
59.1% |
532,693
|
$3,431,464 |
| Baker Bros. Advisors Lp |
Non-Executive Director |
MADRIGAL PHARMACEUTICALS, INC. (MDGL)
|
2023-12-14 |
$221.20 |
11.2% |
101,792
|
$22,516,577 |
| Baker Bros. Advisors Lp |
Non-Executive Director |
MADRIGAL PHARMACEUTICALS, INC. (MDGL)
|
2023-12-12 |
$218.31 |
12.7% |
34,578
|
$7,548,616 |
| Baker Bros. Advisors Lp |
Non-Executive Director |
MADRIGAL PHARMACEUTICALS, INC. (MDGL)
|
2023-11-21 |
$188.47 |
30.5% |
64,350
|
$12,128,340 |
| Baker Bros. Advisors Lp |
Non-Executive Director |
MADRIGAL PHARMACEUTICALS, INC. (MDGL)
|
2023-11-20 |
$178.11 |
38.1% |
67,079
|
$11,947,280 |
| Baker Bros. Advisors Lp |
Non-Executive Director |
MADRIGAL PHARMACEUTICALS, INC. (MDGL)
|
2023-11-15 |
$158.13 |
55.6% |
49,387
|
$7,809,559 |
| Baker Bros. Advisors Lp |
Non-Executive Director |
MADRIGAL PHARMACEUTICALS, INC. (MDGL)
|
2023-11-14 |
$146.99 |
67.4% |
107,499
|
$15,801,021 |
| Baker Bros. Advisors Lp |
Non-Executive Director |
Neoleukin Therapeutics, Inc. (NLTX)
|
2023-08-17 |
$12.81 |
9.0% |
114,267
|
$1,463,487 |
| Baker Bros. Advisors Lp |
Non-Executive Director |
ACADIA PHARMACEUTICALS INC (ACAD)
|
2023-05-24 |
$25.33 |
-36.0% |
896,522
|
$22,707,098 |
| Baker Bros. Advisors Lp |
Non-Executive Director |
Kodiak Sciences Inc. (KOD)
|
2022-06-06 |
$7.77 |
-68.1% |
572,349
|
$4,448,168 |
| Baker Bros. Advisors Lp |
Non-Executive |
Entrada Therapeutics, Inc. (TRDA)
|
2022-06-06 |
$6.37 |
141.7% |
40,947
|
$260,760 |
| Baker Bros. Advisors Lp |
Non-Executive Director |
Kodiak Sciences Inc. (KOD)
|
2022-05-27 |
$6.75 |
-63.2% |
350,406
|
$2,363,748 |
| Baker Bros. Advisors Lp |
Non-Executive |
Entrada Therapeutics, Inc. (TRDA)
|
2022-05-24 |
$5.82 |
164.3% |
48,509
|
$282,447 |
| Baker Bros. Advisors Lp |
Non-Executive |
Entrada Therapeutics, Inc. (TRDA)
|
2022-05-18 |
$5.99 |
157.1% |
71,944
|
$430,701 |
| Baker Bros. Advisors Lp |
Non-Executive Director |
Kodiak Sciences Inc. (KOD)
|
2022-05-18 |
$5.91 |
-58.0% |
456,690
|
$2,696,829 |
| Baker Bros. Advisors Lp |
Non-Executive Director |
TScan Therapeutics, Inc. (TCRX)
|
2022-05-11 |
$1.88 |
199.1% |
1,359,792
|
$2,559,154 |
| Baker Bros. Advisors Lp |
Non-Executive Director |
INCYTE CORP (INCY)
|
2022-03-10 |
$72.24 |
-12.8% |
389,080
|
$28,107,770 |
| Baker Bros. Advisors Lp |
Non-Executive Director |
INCYTE CORP (INCY)
|
2022-02-22 |
$67.96 |
-7.4% |
525,804
|
$35,734,890 |
| Baker Bros. Advisors Lp |
Non-Executive Director |
Kodiak Sciences Inc. (KOD)
|
2022-02-17 |
$54.45 |
-95.4% |
400,965
|
$21,832,153 |
| Baker Bros. Advisors Lp |
Non-Executive Director |
INCYTE CORP (INCY)
|
2022-02-14 |
$66.91 |
-5.9% |
1,598,374
|
$106,952,404 |
| Baker Bros. Advisors Lp |
Non-Executive Director |
Kodiak Sciences Inc. (KOD)
|
2022-01-31 |
$52.02 |
-95.2% |
347,665
|
$18,084,687 |
| Baker Bros. Advisors Lp |
Non-Executive Director |
Kodiak Sciences Inc. (KOD)
|
2022-01-25 |
$57.49 |
-95.7% |
501,111
|
$28,806,796 |
| Baker Bros. Advisors Lp |
Non-Executive Director |
INCYTE CORP (INCY)
|
2021-12-17 |
$72.43 |
-13.1% |
1,595,519
|
$115,558,900 |
| Baker Bros. Advisors Lp |
Non-Executive Director |
Talis Biomedical Corp (TLIS)
|
2021-11-18 |
$65.47 |
-97.9% |
3,333
|
$218,250 |
| Baker Bros. Advisors Lp |
Non-Executive Director |
Kodiak Sciences Inc. (KOD)
|
2021-09-30 |
$95.83 |
-97.4% |
86,932
|
$8,330,572 |
| Baker Bros. Advisors Lp |
Non-Executive Director |
Kodiak Sciences Inc. (KOD)
|
2021-09-16 |
$94.39 |
-97.4% |
31,838
|
$3,005,281 |
| Baker Bros. Advisors Lp |
Non-Executive Director |
Kodiak Sciences Inc. (KOD)
|
2021-09-07 |
$93.31 |
-97.3% |
57,501
|
$5,365,227 |
| Baker Bros. Advisors Lp |
Non-Executive Director |
Kodiak Sciences Inc. (KOD)
|
2021-08-19 |
$87.50 |
-97.2% |
114,396
|
$10,009,957 |
| Baker Bros. Advisors Lp |
Non-Executive Director |
Kodiak Sciences Inc. (KOD)
|
2021-08-13 |
$87.19 |
-97.2% |
102,773
|
$8,960,623 |
| Baker Bros. Advisors Lp |
Non-Executive Director |
TScan Therapeutics, Inc. (TCRX)
|
2021-07-20 |
$15.00 |
-62.5% |
1,425,000
|
$21,375,000 |
| Baker Bros. Advisors Lp |
Non-Executive Director |
Kodiak Sciences Inc. (KOD)
|
2021-06-30 |
$91.72 |
-97.3% |
257,929
|
$23,656,430 |
| Baker Bros. Advisors Lp |
Non-Executive Director |
Talis Biomedical Corp (TLIS)
|
2021-02-17 |
$240.00 |
-99.4% |
416,667
|
$100,000,000 |
| Baker Bros. Advisors Lp |
Non-Executive Director |
Kodiak Sciences Inc. (KOD)
|
2020-11-20 |
$108.00 |
-97.7% |
1,527,777
|
$164,999,916 |
| Baker Bros. Advisors Lp |
Non-Executive Director |
Prelude Therapeutics Inc (PRLD)
|
2020-09-29 |
$19.00 |
-74.7% |
1,578,947
|
$29,999,993 |
| Baker Bros. Advisors Lp |
Non-Executive Director |
Kodiak Sciences Inc. (KOD)
|
2020-09-25 |
$56.65 |
-95.6% |
48,125
|
$2,726,182 |
| Baker Bros. Advisors Lp |
Non-Executive Director |
Kodiak Sciences Inc. (KOD)
|
2020-09-24 |
$51.71 |
-95.2% |
203,047
|
$10,498,591 |
| Baker Bros. Advisors Lp |
Non-Executive Director |
Kodiak Sciences Inc. (KOD)
|
2020-09-08 |
$47.43 |
-94.8% |
322,979
|
$15,318,311 |
| Baker Bros. Advisors Lp |
Non-Executive Director |
Kodiak Sciences Inc. (KOD)
|
2020-08-21 |
$48.23 |
-94.9% |
203,486
|
$9,815,002 |
| Baker Bros. Advisors Lp |
Non-Executive Director |
Neoleukin Therapeutics, Inc. (NLTX)
|
2020-07-07 |
$305.00 |
-95.4% |
21,200
|
$6,466,000 |
| Baker Bros. Advisors Lp |
Non-Executive Director |
INCYTE CORP (INCY)
|
2020-05-28 |
$102.55 |
-38.6% |
2
|
$205 |
| Baker Bros. Advisors Lp |
Non-Executive Director |
ACADIA PHARMACEUTICALS INC (ACAD)
|
2020-03-18 |
$32.05 |
-49.4% |
1,050,000
|
$33,652,026 |
| Baker Bros. Advisors Lp |
Non-Executive Director |
Kodiak Sciences Inc. (KOD)
|
2020-03-18 |
$39.29 |
-93.7% |
150,000
|
$5,893,804 |
| Baker Bros. Advisors Lp |
Non-Executive Director |
Kodiak Sciences Inc. (KOD)
|
2020-02-26 |
$57.87 |
-95.7% |
377,249
|
$21,830,242 |
|
|
|
|
|
Return |
Profit / (loss) |
Cost |
|
|
|
Total |
|
-53.3% |
$-511,389,748 |
$959,020,075 |